The nomination of Dr. Casey Means as Surgeon General is unlikely to have a significant direct impact on the stock market, as it is primarily a public health appointment. However, the mention of working to reverse the Chronic Disease Epidemic could have implications for the healthcare sector, potentially affecting pharmaceutical and biotechnology stocks. Additionally, the involvement of Robert F. Kennedy, Jr., as Secretary of Health and Human Services, may raise concerns about potential regulatory changes or vaccine policies, which could impact related stocks. Overall, the market is likely to remain neutral, as the nomination is largely a political appointment with limited direct economic implications. Historical patterns suggest that Trump's appointments have had varied effects on the market, depending on the specific industry and regulatory implications. In this case, the lack of clear economic implications makes it difficult to predict a significant market reaction.